| Officer | Age | In this role | Joined | Pay | Source |
|---|---|---|---|---|---|
|
Adi Mohanty
Also a director
Chief Executive Officer
|
57 | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
November 2022 registered direct offering of common stock and warrants to Athyrium affiliates, with a waiver of 7.25% Convertible Notes cash interest as in-kind payment
September 2023 exchange of $50,000,000 of 7.25% Convertible Notes for common stock, pre-funded warrants and warrants
December 2023 purchase of 11.00% / 13.00% Convertible Notes and warrants in exchange for accrued interest on 7.25% Convertible Notes
December 2023 exchange of 7.25% Convertible Notes for 11.00% / 13.00% Convertible Notes and warrants
December 2023 purchase of 11.00% / 13.00% Convertible Notes and warrants
December 2023 exchange of 7.25% Convertible Notes for 11.00% / 13.00% Convertible Notes
December 2023 purchase of 11.00% / 13.00% Convertible Notes and warrants, and exchange of 7.25% Convertible Notes
November 2022 registered direct offering of 800,000 common shares and warrants at $7.50 per share with accompanying warrant
January 2023 issuance of warrants for 90,000 shares to Armistice in exchange for a waiver of lockup provisions
May 2022 contribution of single-molecule detection platform assets to Enumera Molecular, Inc. in exchange for Series A-1 preferred stock
Consulting agreement under which Dr. Kotzin is eligible to receive up to $15,000 per year
Loading...
